Gilead Sciences, Inc. $GILD Stock: Robeco Institutional Asset Management B.V. Reduces Stake

Robeco Institutional Asset Management B.V. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,442,819 shares of the biopharmaceutical company’s stock after selling 17,074 shares during the quarter. Gilead Sciences accounts for 0.6% of Robeco Institutional Asset Management B.V.’s portfolio, making the stock its 29th largest position. Robeco Institutional Asset Management B.V. owned about 0.28% of Gilead Sciences worth $513,152,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $15,393,785,000. State Street Corp boosted its position in Gilead Sciences by 2.3% during the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after buying an additional 1,357,967 shares during the period. Amundi grew its stake in shares of Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after buying an additional 1,018,976 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of Gilead Sciences in the second quarter worth about $1,316,606,000. Finally, Deutsche Bank AG purchased a new stake in shares of Gilead Sciences during the second quarter valued at approximately $918,387,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In related news, CEO Daniel O’Day sold 15,000 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $147.90, for a total transaction of $2,218,500.00. Following the completion of the sale, the chief executive officer owned 566,683 shares in the company, valued at approximately $83,812,415.70. This trade represents a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the sale, the insider directly owned 113,684 shares in the company, valued at $17,759,714.48. This trade represents a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 111,000 shares of company stock worth $15,877,860. 0.30% of the stock is currently owned by insiders.

Gilead Sciences Stock Up 2.2%

NASDAQ GILD opened at $156.51 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $114.02 and a 52 week high of $160.51. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $194.06 billion, a P/E ratio of -58.62 and a beta of 0.31. The stock’s 50-day moving average price is $148.01 and its 200-day moving average price is $137.50.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The firm’s revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.01 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post -0.47 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were issued a dividend of $0.82 per share. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.1%. Gilead Sciences’s payout ratio is currently -122.85%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on GILD. HSBC raised their price target on Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Bank of America upped their target price on shares of Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a research note on Tuesday. Barclays reduced their price objective on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Royal Bank Of Canada boosted their price target on Gilead Sciences from $123.00 to $126.00 and gave the company a “sector perform” rating in a research note on Thursday, October 8th. Finally, Zacks Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $159.63.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Ulcerative colitis trial success strengthens the pipeline. Gilead reported positive Phase 2 SWIFT results for emvistegrast, an oral treatment for active ulcerative colitis. The data were described as “highly competitive,” supporting management’s strategy to expand into immunology and inflammatory bowel disease. Success in a large market could diversify Gilead beyond its HIV franchise. Gilead’s highly competitive mid-stage ulcerative colitis data validate I&I push
• Positive Sentiment: Bank of America raised its price target and maintained a Buy rating. The target increased from $168 to $172, implying roughly 10% upside from the referenced price and signaling confidence in Gilead’s earnings outlook and pipeline prospects.
• Positive Sentiment: Recent FDA decisions add commercial catalysts. Gilead received approval for the Bixlenvo HIV regimen, a first-line label expansion for Trodelvy in metastatic triple-negative breast cancer, and approval for Hepcludex in chronic hepatitis delta. The company will also present 28 HIV and antiviral research findings at IDWeek 2026, potentially providing additional clinical updates. How Investors Are Reacting To Gilead Sciences FDA Drug Approvals
• Positive Sentiment: Analyst and quantitative sentiment improved. Gilead was upgraded to Zacks Rank #2 (Buy), reflecting improving expectations for earnings prospects. Separately, 43 ETFs added Gilead shares, indicating some institutional demand. Gilead rating upgrade to Buy
• Neutral Sentiment: Investors are weighing acquisitions against Gilead’s dependable HIV cash flow. Biktarvy and other HIV products continue to support recurring revenue and the dividend, but acquisitions such as Arcellx and Tubulis have increased research and integration costs. Gilead reportedly recorded a substantial trailing loss as it absorbs those investments.
• Negative Sentiment: ETF selling and near-term profitability concerns could limit gains. ETFs were also reported as net sellers of Gilead on October 16, while coverage noted that the ulcerative-colitis trial win initially failed to lift the stock. Investors may remain focused on acquisition-related expenses and the path back to sustainable positive earnings. ETFs Are Net Sellers of Gilead Sciences

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.